| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | SID 26681509 | CTRPv2 | pan-cancer | AAC | 0.033 | 0.4 |
| mRNA | TPCA-1 | CTRPv2 | pan-cancer | AAC | 0.028 | 0.4 |
| mRNA | MST-312 | CTRPv2 | pan-cancer | AAC | -0.03 | 0.4 |
| mRNA | NVP-231 | CTRPv2 | pan-cancer | AAC | 0.028 | 0.4 |
| mRNA | trifluoperazine | CTRPv2 | pan-cancer | AAC | 0.032 | 0.4 |
| mRNA | Ko-143 | CTRPv2 | pan-cancer | AAC | -0.031 | 0.4 |
| mRNA | ruxolitinib | CTRPv2 | pan-cancer | AAC | 0.029 | 0.4 |
| mRNA | Erlotinib | CTRPv2 | pan-cancer | AAC | 0.029 | 0.4 |
| mRNA | Bortezomib | gCSI | pan-cancer | AAC | 0.045 | 0.4 |
| mRNA | BRD-K16147474 | CTRPv2 | pan-cancer | AAC | 0.033 | 0.4 |